about
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerNuclear transport of galectin-3 and its therapeutic implicationsStructural characterization of human galectin-4 C-terminal domain: elucidating the molecular basis for recognition of glycosphingolipids, sulfated saccharides and blood group antigensGalectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cellsOptical properties of prodigiosin and obatoclax: action spectroscopy and theoretical calculations.Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling.Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Three-dimensional bio-printing: A new frontier in oncology research.Structural characterisation of human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol, lactose, 3'-sulfo-lactose, and 2'-fucosyllactose.Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.[Galectins, a class of unconventional lectins].Atractylochromene Is a Repressor of Wnt/β-Catenin Signaling in Colon Cancer Cells.A case of intravascular large B cell lymphoma: New clinical and immunohistochemical findings.Molecular docking studies of bioactive compounds from Annona muricata Linn as potential inhibitors for Bcl-2, Bcl-w and Mcl-1 antiapoptotic proteins.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
P2860
Q26744538-1BDA7FC2-EECF-4CE9-AC66-DA4727AD5801Q26824889-C67314E0-3890-4916-A4BE-8C6487BAB1CCQ27701016-EBAB9624-999C-4B7A-9496-26642455CD22Q34654834-62A59C0F-3006-418D-9B80-F28BA1A92A57Q35676827-C2470D65-6C4C-46A3-97F7-C521148D92D3Q36260595-5335AB2F-AA1B-4226-9FCD-3F17D83B5C43Q36642752-AB61F3FF-689B-41F0-8AC8-069D82F4F05EQ37642457-A93736A7-EC66-4A17-BF8C-762A41E4FF9CQ38294060-0AA8A60E-5CFD-4948-8845-0FEE723C175AQ38805260-A192BB89-1BF5-46A0-8DE4-BC59816C5D0FQ41172644-11D67C6E-5642-407D-856B-D1CB698F579DQ41830983-27ACEA79-90B8-413D-8E5A-4BD525915F92Q44525382-1ADE3FC3-6CF5-4980-B05F-F760CABF2236Q47284705-E9955E65-D51D-4F6F-AFEF-0B542E9D7540Q47941645-78A943F3-9779-44A3-8B28-D0B61530267CQ48159180-14A227B1-A36F-46E2-83A2-97C3AC4B5BCDQ48270428-DFF7E9BC-B9FF-453A-9E8D-993E93B17968
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Why anti-Bcl-2 clinical trials fail: a solution
@ast
Why anti-Bcl-2 clinical trials fail: a solution
@en
type
label
Why anti-Bcl-2 clinical trials fail: a solution
@ast
Why anti-Bcl-2 clinical trials fail: a solution
@en
prefLabel
Why anti-Bcl-2 clinical trials fail: a solution
@ast
Why anti-Bcl-2 clinical trials fail: a solution
@en
P2093
P2860
P1476
Why anti-Bcl-2 clinical trials fail: a solution
@en
P2093
P2860
P2888
P304
P356
10.1007/S10555-013-9450-8
P577
2014-03-01T00:00:00Z
P6179
1016843994